Shi, Yuankai

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,183

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Wu, Y.-L., Lu, S., Cheng, Y., Zhou, C., Wang, J., Mok, T., Zhang, L., Tu, H.-Y., Wu, L., Feng, J., et al. (2019) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 357

Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study

Shi, Y., Zhao, Y., Yang, S., Zhou, J., Zhang, L., Chen, G., Fang, J., Zhu, B., Li, X., Shu, Y., et al. (2022) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 27

Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial

Shi, Y., Wu, L., Ji, Y., Chen, G., Li, B., Bi, M., Yang, R., Miao, L., Zhang, G., Gao, H., et al. (2025) · The Lancet Respiratory Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 16

Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial

Shi, Y., Bi, M., Li, Q., Wang, G., Chen, J., Li, M., Shi, J., Mei, J., Ji, Y., Xia, Q., et al. (2025) · Cancer Pathogenesis and Therapy

Lung Cancer Treatments and MutationsBiosimilars and Bioanalytical Methods

Cited by 2